The company's proprietary technologies allow for the differentiation of stem cells into insulin-secreting beta cells and various neural cells, including Oligodendrocytes and Astrocytes. Kadimastem has two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells and astrocytes, respectively, with the goal of implanting them into patients and affecting disease progression. The company partners with pharmaceutical companies to screen potential drug compounds on its stem-cell derived cells, using a cell-based High Content Screening (HCS) system. Kadimastem is based in Nes Ziona, Israel and is developing revolutionary regenerative therapies based on stem cells.